NODia

Development of novel inhibitors of the nNOS-PIN complex for the treatment of type 2 diabetes.

Project development between the University of Montpellier and SATT AxLR

The nNOS and PIN proteins are both involved in the regulation of insulin secretion (Lajoix et al., Diabetes, 2001; 2004; 2006) and in muscle glucose sensitivity (Stamler et al., Physiol Rev, 2001) in rats and humans. Furthermore, molecular abnormalities in nNOS, particularly a reduction in its catalytic activity, contribute to pancreatic β-cell and muscle dysfunction in animal models of prediabetes (Mezghenna et al. Diabetologia, 2011; 2014).

Selective inhibition of the interaction between nNOS and its inhibitor PIN is a way to restore normal nNOS catalytic activity and correct the pancreatic and muscular defects associated with diabetes. This strategy therefore holds significant potential for the development of new antidiabetic treatments targeting patients with newly diagnosed diabetes.

The goal of the project is to identify novel chemical compounds capable of modulating this molecular complex and exhibiting antidiabetic properties.